Bank Of Montreal Alaunos Therapeutics, Inc. Transaction History

Bank Of Montreal

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$0.04 - $0.13 $217 - $706	5,434 Added 37.16%	20,056 $1,000
Q2 2023 Aug 02, 2023	BUY	$0.43 - $0.65 $6,287 - $9,504	14,622 New	14,622 $7,000
Q1 2023 Jun 13, 2024	BUY	$0.46 - $0.81 $6,726 - $11,843	14,622 New	14,622 $9,000
Q3 2022 Nov 10, 2022	BUY	$1.04 - $322.5 $54,912 - $17 Million	52,800 Added 28.88%	235,600 $481,000
Q2 2022 Aug 11, 2022	BUY	$0.41 - $1.24 $74,948 - $226,672	182,800 New	182,800 $231,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.